

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Original). A peptide originating from mammalian IL1 $\beta$  or TNF $\alpha$  cytokines, homologous to one of the following peptides of human IL1 $\beta$  or TNF $\alpha$  cytokines:

80 ISRIAVSYQTKVNLLS 95 (SEQ ID NO:2)

140 DYLDFAESGQVY 150 (SEQ ID NO:5)

3 VKSLNCTLRDSQQKSL 18 (SEQ ID NO:7)

45 SFVQGEESNDKIP 57 (SEQ ID NO:8)

89 NYPKKKMEKRFFVFNKIEI 106 (SEQ ID NO:9)

121 YISTSQAENMPVFLG 135 (SEQ ID NO:4)

143 ITDFTMQFVSS 153 (SEQ ID NO:10)

2 (Original). A peptide according to claim 1, wherein the human TNF $\alpha$  cytokine peptide sequence is ISRIAVSYQTKVNLLS (SEQ ID NO:2)

3 (Original). A peptide according to claim 1, wherein the human TNF $\alpha$  cytokine peptide sequence is DYLDFAESGQVY (SEQ ID NO:5)

4 (Original). A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is VKSLNCTLRDSQQKSL (SEQ ID NO:7).

5 (Original). A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is SFVQGEESNDKIP (SEQ ID NO:8).

6 (Original). A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is NYPKKKMEKRFVFNKIEI (SEQ ID NO:9).

7 (Original). A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is YISTSQAENMPVFLG (SEQ ID NO:4).

8 (Original). A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine sequence is ITDFTMQFVSS (SEQ ID NO:10).

10 (Amended). A derivative of the peptide according to ~~any of claims~~ claim 1 to 9.

11 (Amended). A peptide according to ~~one of claims~~ claim 1 to 10 characterized in that it consists of less than 30 amino acids.

12 (Amended). A derivative of a peptide as defined in ~~any one of claims~~ claim 1 to 11 by deletion, substitution, addition, cyclization, stereochemical modification (use of D series amino acids) or functionalization (such as acylation) of one or more amino acids of said peptide.

13 (Amended). An immunogenic compound characterized in that it comprises a peptide or peptide derivative as defined in ~~any one of claims~~ claim 1 to 12, it being understood that it comprises no other epitopes of said cytokine and in that it is capable of generating in a subject antibodies recognizing the native cytokine.

14 (Amended). A peptide or peptide derivative or immunogenic compound as defined in ~~any one of claims~~ claim 1 to 13 for use in a method for preventive or therapeutic treatment of the human body.

15 (Amended). A peptide or peptide derivative or immunogenic compound as defined in ~~any one of claims~~ claim 1 to 13 for use in a method for preventive or therapeutic treatment of the animal body (veterinary).

Claim 16 (Cancelled).

17 (Amended). A pharmaceutical composition which contains at least one peptide or peptide derivative or immunogenic compound as defined in ~~any one of claims~~ claim 1 to ~~15~~ as active ingredient.

18 (Amended). Monoclonal or oligoclonal antibody specific to a peptide defined in ~~any one of claims~~ claim 1 to ~~15~~.

Claim 19 (Cancelled).

20 (Original). A method for the treatment of a disease associated with the pathogenic overproduction of IL1 $\beta$  or TNF $\alpha$ , comprising administering to a patient in need thereof an antibody as defined in claim 18 to treat the disease associated with the pathogenic overproduction of IL1 $\beta$  or TNF $\alpha$ .

21 (Amended). A method for the treatment or prevention of diseases associated with the pathogenic overproduction of IL1 $\beta$  or TNF $\alpha$ , comprising administering to a patient in need thereof a peptide or peptide derivative or immunogenic compound as defined in ~~any one of claims~~ claim 1 to ~~15~~ to treat or inhibit the disease associated with the pathogenic overproduction of IL1 $\beta$  or TNF $\alpha$ .